

해외 바이오의약품 임상 현황 (2020.07.27~2020.08.02)

한국바이오의약품협회, 2020.8.4.
출처: ClinicalTrials.gov

○ 미국 80건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04492488	A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer	Advanced Solid Tumors Advanced or Metastatic Gastric Cancer Advanced or Metastatic Gastroesophageal Junction Cancer	Drug: MRG002	Shanghai Miracogen Inc.	Phase 1 Phase 2
NCT04464759	A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma	Melanoma	Drug: Nivolumab Drug: Hydroxychloroquine Drug: Ipilimumab	Ravi Amaravadi, MD Bristol-Myers Squibb Abramson Cancer Center of the University of Pennsylvania	Phase 1 Phase 2
NCT04454528	BreastVax: Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer	Breast Cancer	Radiation: Hypofractionated radiotherapy Drug: Pembrolizumab infusion Procedure: Blood and tissue sampling	University of Pennsylvania	Phase 1 Phase 2
NCT04379518	Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients	Malignant Neoplasm SARS Coronavirus 2 Infection	Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI) AIM ImmunoTech Inc.	Phase 1 Phase 2
NCT04333706	A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)	Breast Metastatic Triple Negative Cancer Disseminated Tumor Cell	Drug: Capecitabine Combination Product: Sarilumab 150mg or 200 mg plus Capecitabine Combination Product: Sarilumab 150mg plus Capecitabine	University of Florida National Institutes of Health (NIH)	Phase 1 Phase 2
NCT04129515	NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis	Metastatic Melanoma Melanoma Brain Metastasis	Device: NovoTTF-200A Drug: Pembrolizumab	Eric Wong, MD Dana-Farber Cancer Institute	Phase 1 Phase 2
NCT04108481	Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer	Colorectal Cancer Metastatic Colon Cancer Metastatic Colorectal Cancer Rectal Cancer Liver Metastasis Colon Cancer Colo-rectal Cancer Colorectal Adenocarcinoma Colorectal Neoplasms Liver Metastases Colorectal Carcinoma	Drug: Durvalumab Radiation: Yttrium-90 RadioEmbolization	University of Iowa Biocompatibles UK Ltd AstraZeneca	Phase 1 Phase 2
NCT04477642	Abatacept for Patients With COVID-19 and Respiratory Distress	COVID-19	Drug: Abatacept	Beth Israel Deaconess Medical Center Boston Children's Hospital Bristol-Myers Squibb Brigham and Women's Hospital	Phase 1 Phase 2
NCT04467723	Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC	NSCLC Stage IV NSCLC, Recurrent	Drug: Atezolizumab	University of Kansas Medical Center parkview cancer institute	Phase 1 Phase 2
NCT04421560	Pembrolizumab, Ibrutinib and Rituximab in PCNSL	Primary Central Nervous System Lymphoma Recurrent Cancer	Drug: Ibrutinib Drug: Pembrolizumab Drug: Rituximab	Dana-Farber Cancer Institute Merck Sharp & Dohme Corp.	Phase 1 Phase 2
NCT04495478	A Study of Ramucirumab (LY3009806) in Healthy Participants	Healthy	Drug: Ramucirumab - IV Drug: Placebo - IV Drug: Ramucirumab - SC Drug: Placebo - SC	Eli Lilly and Company	Phase 1
NCT04495257	A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)	Advanced Melanoma Renal Cell Carcinoma	Drug: Nivolumab Drug: Ipilimumab Drug: APX005M	Yale University Apexigen, Inc.	Phase 1
NCT04493567	Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe	Healthy Participants	Drug: BMS-986036	Bristol-Myers Squibb	Phase 1
NCT04493203	Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma	Advanced Melanoma Unresectable Melanoma	Drug: Nivolumab Drug: Axitinib	Yana Najjar Pfizer Bristol-Myers Squibb University of Pittsburgh	Phase 2
NCT04490486	Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19	COVID-19 Acute Respiratory Distress Syndrome Corona Virus Infection	Biological: UCMSCs Other: Placebo	Joshua M Hare University of Miami	Phase 1
NCT04477629	Belatacept in De Novo Heart Transplantation	Heart Transplantation	Drug: Belatacept	Marlena V. Habal Bristol-Myers Squibb Columbia University	Phase 2
NCT04475523	Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies	Solid Tumor	Drug: CI-8993	Curis, Inc.	Phase 1
NCT04474847	Abatacept for the Treatment of Giant Cell Arteritis	Giant Cell Arteritis	Drug: Abatacept Drug: Placebo	University of Pennsylvania	Phase 3
NCT04463004	Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation	COVID-19 Sars-CoV2 Pneumonia	Drug: Mavrilimumab Drug: Placebos	Virginia Commonwealth University Kiniksa Pharmaceuticals, Ltd.	Phase 2
NCT04462848	Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions	Corona Virus Infection	Biological: anti-SARS-CoV-2 human convalescent plasma	University of California, Los Angeles	Phase 1
NCT04442581	Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer	Advanced Hepatocellular Carcinoma BCLC Stage B Hepatocellular Carcinoma BCLC Stage C Hepatocellular Carcinoma	Drug: Cabozantinib S-malate Biological: Pembrolizumab	University of Washington National Cancer Institute (NCI)	Phase 2
NCT04430036	AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer	Urinary Bladder Neoplasms	Drug: AGEN1884 Drug: AGEN2034 Drug: Cisplatin Drug: Gemcitabine	The University of Texas Health Science Center at San Antonio	Phase 2
NCT04429321	Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary	Renal Cell Carcinoma Renal Cell Carcinoma Stage IV	Drug: Nivolumab Drug: Ipilimumab Device: bland embolization	Abramson Cancer Center of the University of Pennsylvania	Phase 1
NCT04422912	Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV)	Mucosal -Dominant Pemphigus Vulgaris	Biological: DSG3-CAART	Cabaletta Bio	Phase 1

해외 바이오의약품 임상 현황 (2020.07.27 ~ 2020.08.02)

한국바이오의약품협회, 2020.8.4.
출처: ClinicalTrials.gov

NCT04410900	Vaccine Responsiveness After CAR-T Cell Therapy	B-Cell Neoplasm	Biological: Wistar Rabies Virus Strain PM-1503-3M Vaccine Procedure: Biospecimen Collection	Fred Hutchinson Cancer Research Center National Institutes of Health (NIH) National Cancer Institute (NCI)	Phase 1
NCT04404283	Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL	Diffuse Large B-cell Lymphoma	Drug: Brentuximab vedotin Drug: Rituximab Drug: Lenalidomide Other: Placebo	Seattle Genetics, Inc.	Phase 3
NCT04401995	Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab	Melanoma	Drug: CMP-001 Biological: Nivolumab Other: [18F]F-AraG PET/CT	Diwakar Davar Checkmate Pharmaceuticals CellSight Technologies, Inc. University of Pittsburgh	Phase 2
NCT04401410	Anti-SARS Cov-2 T Cell Infusions for COVID 19	SARS-CoV 2 Viral Infection COVID 19	Biological: Partially HLA-matched Virus Specific T cells (VSTs)	Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine The Methodist Hospital System AlloVir	Phase 1
NCT04397003	Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) and Tremelimumab in Extensive Stage Small Cell Lung Cancer	Extensive-stage Small Cell Lung Cancer	Biological: Neoantigen DNA vaccine Drug: Durvalumab Drug: Tremelimumab Device: TDS-IM v1.0 System Procedure: Peripheral blood draws	Washington University School of Medicine AstraZeneca	Phase 2
NCT04395079	Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies	Metastatic Malignant Female Reproductive System Neoplasm Platinum-Resistant Malignant Female Reproductive System Neoplasm Recurrent Malignant Female Reproductive System Neoplasm Refractory Malignant Female Reproductive System Neoplasm	Biological: Durvalumab Radiation: Internal Radiation Therapy Biological: Tremelimumab	Jonsson Comprehensive Cancer Center	Phase 2
NCT04387227	Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma	Drug: Carboplatin Biological: Pembrolizumab	University of Washington National Cancer Institute (NCI) United States Department of Defense	Phase 2
NCT04375631	CLAG-M Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia	Recurrent Acute Myeloid Leukemia Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory Chronic Myelomonocytic Leukemia Refractory Mixed Phenotype Acute Leukemia Refractory Myelodysplastic Syndrome Refractory Acute Leukemia of Ambiguous Lineage Refractory Acute Undifferentiated Leukemia	Drug: Cladribine Drug: Cyclophosphamide Drug: Cyclosporine Drug: Cytarabine Biological: Filgrastim Procedure: Hematopoietic Cell Transplantation Drug: Mitoxantrone Drug: Mycophenolate Mofetil Drug: Mycophenolate Sodium Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 1
NCT04375527	Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma	Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Locally Advanced Cutaneous Melanoma Metastatic Cutaneous Melanoma Pathologic Stage III Cutaneous Melanoma AJCC v8 Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Pathologic Stage IIID Cutaneous Melanoma AJCC v8 Pathologic Stage IV Cutaneous Melanoma AJCC v8 Unresectable Cutaneous Melanoma	Drug: Binimetinib Biological: Nivolumab Other: Questionnaire Administration	Jonsson Comprehensive Cancer Center	Phase 2
NCT04372927	ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy	Locally Advanced Lung Non-Small Cell Carcinoma Stage III Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC v8	Drug: Cisplatin Biological: Durvalumab Drug: Etoposide Radiation: Hypofractionated Radiation Therapy Drug: Pemetrexed	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 2
NCT04371666	A Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids, in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)	Duchenne Muscular Dystrophy	Drug: Pamrevlumab Drug: Placebo	FibroGen	Phase 3
NCT04370301	Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis	Primary Myelofibrosis Secondary Myelofibrosis	Drug: Cyclophosphamide Drug: JAK Inhibitor Drug: Fludarabine Biological: Granulocyte Colony-Stimulating Factor Drug: Melphalan Drug: Mycophenolate Mofetil Procedure: Peripheral Blood Stem Cell Transplantation Drug: Tacrolimus Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2
NCT04362501	Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)	Chronic Sinusitis	Biological: dupilumab Drug: placebo	Johns Hopkins University	Phase 2
NCT04359784	Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy	B-Cell Non-Hodgkin Lymphoma	Biological: Anakinra Biological: Axicabtagene Ciloleucel	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) Sobi	Phase 2
NCT04354025	Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML	Refractory Acute Myeloid Leukemia Relapsed Acute Myeloid Leukemia	Biological: Cytokine induced memory-like NK cells Drug: Fludarabine Drug: Ara-C Drug: G-CSF Drug: Interleukin-2 Procedure: Leukapheresis	Washington University School of Medicine	Phase 2
NCT04348747	Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Malignant Neoplasm in the Brain Metastatic Triple-Negative Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8	Biological: Anti-HER2/HER3 Dendritic Cell Vaccine Drug: Celecoxib Biological: Pembrolizumab Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2
NCT04337827	Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder	Post-transplant Lymphoproliferative Disorder	Drug: Rituximab Drug: Acalabrutinib Diagnostic Test: CT scans	Deepa Jagadeesh Case Comprehensive Cancer Center	Phase 2
NCT04336943	Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load	Biochemically Recurrent Prostate Carcinoma Prostate Adenocarcinoma	Biological: Durvalumab Drug: Olaparib Other: Quality-of-Life Assessment Other: Questionnaire Administration	University of Washington National Cancer Institute (NCI) AstraZeneca	Phase 2

해외 바이오의약품 임상 현황 (2020.07.27~2020.08.02)

한국바이오의약품협회, 2020.8.4.
출처: ClinicalTrials.gov

NCT04329065	Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer	Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8	Biological: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine Drug: Paclitaxel Biological: Trastuzumab Biological: Pertuzumab	University of Washington National Cancer Institute (NCI) United States Department of Defense	Phase 2
NCT04274166	Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	Pyoderma Gangrenosum	Drug: secukinumab 150 mg (2 injections per dose)	Wake Forest University Health Sciences Novartis	Phase 2
NCT04267120	Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)	Renal Cell Carcinoma	Drug: Lenvatinib Drug: Pembrolizumab Procedure: Research blood collection	Washington University School of Medicine Merck Sharp & Dohme Corp.	Phase 2
NCT04236479	Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)	Congenital Heart Disease (CHD)	Biological: BM-MSC	Catherine Bollard Children's National Research Institute	Phase 1
NCT04195633	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies	Acute Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Adult Diffuse Large Cell Lymphoma Anaplastic Large Cell Lymphoma Burkitt Lymphoma Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelomonocytic Leukemia Hodgkin Lymphoma Lymphoblastic Lymphoma Lymphoplasmacytic Lymphoma Mantle Cell Lymphoma Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Polymorphocytic Leukemia Refractory Chronic Lymphocytic Leukemia Refractory Follicular Lymphoma Refractory Marginal Zone Lymphoma Refractory Small Lymphocytic Lymphoma	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Cyclophosphamide Drug: Cyclosporine Biological: Filgrastim Drug: Fludarabine Drug: Mycophenolate Mofetil Drug: Mycophenolate Sodium Radiation: Total-Body Irradiation Drug: Treosulfan	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2
NCT04190056	Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8	Biological: Pembrolizumab Drug: Tamoxifen Drug: Vorinostat	University of California, San Francisco Merck Sharp & Dohme Corp.	Phase 2
NCT04169711	Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma	Clear Cell Renal Cell Carcinoma	Drug: ARO-HIF2	Arrowhead Pharmaceuticals	Phase 1
NCT04169009	Persistence of Protection by Shingrix	Herpes Zoster	Biological: Zostavax Biological: Shingrix	University of Colorado, Denver National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
NCT04150640	P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric	Esophageal Adenocarcinoma Gastric Adenocarcinoma	Drug: Nal-IRI Drug: Oxaliplatin Drug: 5-FU Drug: Trastuzumab	University of Wisconsin, Madison Psen	Phase 2
NCT04150029	A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy	Acute Myeloid Leukemia	Drug: MBG453 Drug: Venetoclax Drug: Azacitidine	Novartis Pharmaceuticals Novartis	Phase 2
NCT04030052	Emicizumab PUPs and Nuwiq ITI Study	Hemophilia A	Drug: Nuwiq (low dose protocol) Drug: Emicizumab Drug: Nuwiq (Atlanta protocol)	Emory University	Phase 3
NCT03943901	Split-Dose R-CHOP for Older Adults With DLBCL	Diffuse Large B Cell Lymphoma DLBCL Cancer	Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Biological: Pegfilgrastim	University of Wisconsin, Madison Medical College of Wisconsin	Phase 2
NCT03887741	Plasmapheresis Versus Plasma Infusion From Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression	Mild Cognitive Impairment	Biological: Plasmapheresis Biological: Plasma infusion	Mayo Clinic	Phase 1
NCT04466098	Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)	Acute Respiratory Distress Syndrome ARDS (Moderate or Severe) COVID-19 Pneumonia	Biological: Mesenchymal stromal cells Other: Placebo	Masonic Cancer Center, University of Minnesota	Phase 2
NCT04205812	Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)	Metastatic Squamous Non-Small Cell Lung Cancer Metastatic Nonsquamous Non-Small Cell Lung Cancer	Drug: Retifanlimab Drug: Placebo Drug: Pemetrexed Drug: Cisplatin Drug: Carboplatin Drug: Paclitaxel Drug: nab-Paclitaxel	Incyte Corporation Zai Lab (Shanghai) Co., Ltd.	Phase 3
NCT04460456	A Study of SBT6050 in Patients With Advanced HER2 Expressing Solid Tumors	HER2 Positive Solid Tumors	Drug: SBT6050	Silverback Therapeutics	Phase 1
NCT04328714	Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease	Acute Leukemia Myelodysplastic Syndromes	Drug: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells	Edwin Horwitz Emory University	Phase 1
NCT04157127	Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma	Pancreatic Adenocarcinoma Pancreatic Cancer	Biological: Autologous DC vaccine	Baylor College of Medicine Cancer Cures for Kids	Phase 1
NCT04428151	Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)	Squamous Cell Carcinoma of Head and Neck	Drug: Pembrolizumab Drug: Lenvatinib Drug: Docetaxel Drug: Capecitabine Drug: Paclitaxel Drug: Cetuximab	Merck Sharp & Dohme Corp. Eisai Inc.	Phase 2
NCT04364620	AB-1685 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer	NSCLC Stage IV	Drug: AB-1685 Drug: Docetaxel	Alethia Biotherapeutics	Phase 2
NCT04491604	The Objective of This Study is to Compare the Efficacy and Safety of Beremagene Geperpavec (B-VEC) Topical Gel With That of Placebo for the Treatment of Dystrophic Epidermolysis Bullosa (DEB).	Dystrophic Epidermolysis Bullosa Recessive Dystrophic Epidermolysis Bullosa Dominant Dystrophic Epidermolysis Bullosa	Biological: Topical Beremagene Geperpavec Other: Placebo	Krystal Biotech, Inc.	Phase 3

해외 바이오의약품 임상 현황 (2020.07.27 ~ 2020.08.02)

한국바이오의약품협회, 2020.8.4.
출처: ClinicalTrials.gov

NCT04300296	PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus	Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris	Drug: Cutaneous lichen planus secukinumab 300 mg Q4W Drug: Cutaneous lichen planus placebo Drug: Mucosal lichen planus placebo Drug: Lichen planopilaris placebo Drug: Mucosal lichen planus secukinumab 300 mg Q4W Drug: Lichen planopilaris secukinumab 300 mg Q4W	Novartis Pharmaceuticals Novartis	Phase 2
NCT04240704	Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)	Non-Hodgkins Lymphoma Chronic Lymphocytic Leukemia	Drug: JBH492	Novartis Pharmaceuticals Novartis	Phase 1
NCT04442022	A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Relapsed/Refractory Diffuse Large B-cell Lymphoma	Drug: Selinexor (combination therapy) Drug: Placebo matching for Selinexor (combination therapy) Drug: Rituximab (combination therapy) Drug: Gemcitabine (combination therapy) Drug: Dexamethasone (combination therapy) Drug: Cisplatin (combination therapy) Drug: Selinexor (continuous therapy) Drug: Placebo matching for Selinexor (continuous therapy)	Karyopharm Therapeutics Inc	Phase 2 Phase 3
NCT04298918	A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer	Breast Cancer	Drug: Placebo Drug: Venetoclax Drug: Trastuzumab emtansine	Hoffmann-La Roche	Phase 1 Phase 2
NCT04494425	Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer	Advanced or Metastatic Breast Cancer	Drug: Trastuzumab deruxtecan Drug: Capecitabine Drug: Paclitaxel Drug: Nab-Paclitaxel	AstraZeneca Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo	Phase 3
NCT04471428	Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy	Carcinoma, Non-Small-Cell Lung	Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel	Hoffmann-La Roche Exelixis	Phase 3
NCT04470427	A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19	SARS-CoV-2	Biological: mRNA-1273 Biological: Placebo	ModernaTX, Inc Biomedical Advanced Research and Development Authority National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3
NCT04422210	A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).	Small Cell Lung Cancer	Drug: Venetoclax Drug: Atezolizumab Drug: Carboplatin Drug: Etoposide	Hoffmann-La Roche	Phase 1
NCT04340193	A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer	Liver Cancer	Biological: nivolumab Biological: ipilimumab	Bristol-Myers Squibb	Phase 3
NCT04338269	A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment	Carcinoma, Renal Cell	Drug: Atezolizumab Drug: Cabozantinib	Hoffmann-La Roche Exelixis	Phase 3
NCT04264806	A Study of Cusatzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: Azacitidine Drug: Cusatzumab	Janssen Research & Development, LLC argenx BVBA	Phase 2
NCT04221477	A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis	Lupus Nephritis	Drug: Obinutuzumab Drug: MMF Drug: Prednisone Drug: Placebo Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Hoffmann-La Roche	Phase 3
NCT04453293	Immunization With BCG Vaccine to Prevent Tuberculosis Infection	Tuberculosis Infection	Biological: BCG (Tokyo 172) vaccine Drug: Placebo	Henry M. Jackson Foundation for the Advancement of Military Medicine United States Department of Defense Uniformed Services University of the Health Sciences	Phase 3
NCT04416451	Study of Rituximab and Venetoclax in People With Newly Diagnosed Marginal Zone Lymphoma	Marginal Zone Lymphoma	Drug: Rituximab Drug: Venetoclax	Memorial Sloan Kettering Cancer Center AbbVie	Phase 2
NCT04066348	TNF- α Treatment of Blast-Induced Tinnitus	Tinnitus, Noise Induced	Biological: Etanercept Other: Saline	Wayne State University Portland VA Medical Center John D. Dingell VA Medical Center University of Arizona University of Iowa University of Miami University of Illinois at Urbana-Champaign	Phase 2
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04489940	Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMG2) Expressing Triple Negative Breast Cancer	Triple Negative Breast Neoplasms	Drug: Bintrafusp alfa	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2

해외 바이오의약품 임상 현황 (2020.07.27 ~ 2020.08.02)

한국바이오의약품협회, 2020.8.4.
출처: ClinicalTrials.gov

○ 영국 6건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04442022	A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Relapsed/Refractory Diffuse Large B-cell Lymphoma	Drug: Selinexor (combination therapy) Drug: Placebo matching for Selinexor (combination therapy) Drug: Rituximab (combination therapy) Drug: Gemcitabine (combination therapy) Drug: Dexamethasone (combination therapy) Drug: Selinexor (continuous therapy) Drug: Placebo matching for Selinexor (continuous therapy)	Karyopharm Therapeutics Inc	Phase 2 Phase 3
NCT04471428	Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy	Carcinoma, Non-Small-Cell Lung	Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel	Hoffmann-La Roche Exelixis	Phase 3
NCT04221477	A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis	Lupus Nephritis	Drug: Obinutuzumab Drug: MMF Drug: Prednisone Drug: Placebo Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Hoffmann-La Roche	Phase 3
NCT04264806	A Study of Cusatzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: Azacitidine Drug: Cusatzumab	Janssen Research & Development, LLC argenx BVBA	Phase 2
NCT04245085	ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma	EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC	Drug: Atezolizumab Drug: Bevacizumab Drug: Carboplatin Drug: Paclitaxel Drug: Pemetrexed	European Thoracic Oncology Platform Roche Pharma AG	Phase 2
NCT04338269	A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment	Carcinoma, Renal Cell	Drug: Atezolizumab Drug: Cabozantinib	Hoffmann-La Roche Exelixis	Phase 3

○ 프랑스 9건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04428047	Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma	Squamous Cell Carcinoma of Head and Neck	Drug: bintrafusp alfa	UNICANCER Merck KGaA, Darmstadt, Germany	Phase 2
NCT04471428	Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy	Carcinoma, Non-Small-Cell Lung	Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel	Hoffmann-La Roche Exelixis	Phase 3
NCT04340193	A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer	Liver Cancer	Biological: nivolumab Biological: ipilimumab	Bristol-Myers Squibb	Phase 3
NCT04338269	A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment	Carcinoma, Renal Cell	Drug: Atezolizumab Drug: Cabozantinib	Hoffmann-La Roche Exelixis	Phase 3
NCT04264806	A Study of Cusatzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: Azacitidine Drug: Cusatzumab	Janssen Research & Development, LLC argenx BVBA	Phase 2
NCT04221477	A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis	Lupus Nephritis	Drug: Obinutuzumab Drug: MMF Drug: Prednisone Drug: Placebo Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Hoffmann-La Roche	Phase 3
NCT04442022	A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Relapsed/Refractory Diffuse Large B-cell Lymphoma	Drug: Selinexor (combination therapy) Drug: Placebo matching for Selinexor (combination therapy) Drug: Rituximab (combination therapy) Drug: Gemcitabine (combination therapy) Drug: Dexamethasone (combination therapy) Drug: Cisplatin (combination therapy) Drug: Selinexor (continuous therapy) Drug: Placebo matching for Selinexor (continuous therapy)	Karyopharm Therapeutics Inc	Phase 2 Phase 3
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04494425	Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer	Advanced or Metastatic Breast Cancer	Drug: Trastuzumab deruxtecan Drug: Capecitabine Drug: Paclitaxel Drug: Nab-Paclitaxel	AstraZeneca Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo	Phase 3

해외 바이오의약품 임상 현황 (2020.07.27 ~ 2020.08.02)

한국바이오의약품협회, 2020.8.4.
출처: ClinicalTrials.gov

○ 독일 12건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04442022	A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Relapsed/Refractory Diffuse Large B-cell Lymphoma	Drug: Selinexor (combination therapy) Drug: Placebo matching for Selinexor (combination therapy) Drug: Rituximab (combination therapy) Drug: Gemcitabine (combination therapy) Drug: Dexamethasone (combination therapy) Drug: Cisplatin (combination therapy) Drug: Selinexor (continuous therapy) Drug: Placebo matching for Selinexor (continuous therapy)	Karyopharm Therapeutics Inc	Phase 2 Phase 3
NCT04444492	Combination of Ranibizumab and Targeted Laser Photocoagulation	Central Retinal Vein Occlusion With Macular Edema	Drug: Ranibizumab Injection Device: Laser photocoagulation	University of Leipzig	Phase 3
NCT04471428	Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy	Carcinoma, Non-Small-Cell Lung	Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel	Hoffmann-La Roche Exelixis	Phase 3
NCT04340193	A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer	Liver Cancer	Biological: nivolumab Biological: ipilimumab	Bristol-Myers Squibb	Phase 3
NCT04338269	A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment	Carcinoma, Renal Cell	Drug: Atezolizumab Drug: Cabozantinib	Hoffmann-La Roche Exelixis	Phase 3
NCT04494425	Study of Trastuzumab Deruxtecán (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer	Advanced or Metastatic Breast Cancer	Drug: Trastuzumab deruxtecán Drug: Capecitabine Drug: Paclitaxel Drug: Nab-Paclitaxel	AstraZeneca Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo	Phase 3
NCT04221477	A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis	Lupus Nephritis	Drug: Obinutuzumab Drug: MMF Drug: Prednisone Drug: Placebo Drug: Methylprednisolone Drug: Acetaminophen Drug: Diphenhydramine	Hoffmann-La Roche	Phase 3
NCT04264806	A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: Azacitidine Drug: Cusatuzumab	Janssen Research & Development, LLC Jargenx BVBA	Phase 2
NCT04464434	Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis	Systemic Sclerosis Systemic Scleroses, Diffuse Scleroderma Scleroderma, Diffuse Autologous Stem Cell Transplantation Cyclophosphamide Mycophenolate Mofetil Treatment Strategy	Procedure: Upfront autologous HSCT	UMC Utrecht ZonMw: The Netherlands Organisation for Health Research and Development Boehringer Ingelheim Milenyi Biotec, Inc.	Phase 3
NCT04245085	ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma	EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC	Drug: Atezolizumab Drug: Bevacizumab Drug: Carboplatin Drug: Paclitaxel Drug: Pemetrexed	European Thoracic Oncology Platform Roche Pharma AG	Phase 2
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04300296	PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus	Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris	Drug: Cutaneous lichen planus secukinumab 300 mg Q4W Drug: Cutaneous lichen planus placebo Drug: Mucosal lichen planus placebo Drug: Lichen planopilaris placebo Drug: Mucosal lichen planus secukinumab 300 mg Q4W Drug: Lichen planopilaris secukinumab 300 mg Q4W	Novartis Pharmaceuticals Novartis	Phase 2

○ 중국 13건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04494503	Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SL	Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma	Drug: APG-2575 Drug: Rituximab Drug: Ibrutinib	Ascentage Pharma Group Inc.	Phase 1 Phase 2
NCT04466904	Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM	Type 2 Diabetes	Drug: IBI362 Drug: Placebo Drug: Dulaglutide	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1 Phase 2
NCT04138992	A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer	Disease Free Survival	Drug: bevacizumab Drug: DDP Drug: Docetaxel Radiation: radiotherapy	Fourth Military Medical University	Phase 2 Phase 3
NCT04485065	Safety and Efficacy of IBI188 With Azacitidine in Newly Diagnosed Higher Risk MDS	Myelodysplastic Syndromes	Drug: IBI188+ azacitidine	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1
NCT04481815	Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	PCNSL	Drug: Rituximab Drug: Lenalidomide Drug: Methotrexate	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2

해외 바이오의약품 임상 현황 (2020.07.27 ~ 2020.08.02)

한국바이오의약품협회, 2020.8.4.
출처: ClinicalTrials.gov

NCT04480788	CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study	T Lymphoblastic Leukemia/Lymphoma Extramedullary NK-T-cell Lymphoma, Nasal Type Peripheral T-cell Lymphoma, Nonspecific Angioimmunoblastic T-cell Lymphoma Enteropathy-Associated T-Cell Lymphoma Anaplastic Large Cell Lymphoma, ALK-negative T-cell Lymphoblastic Leukemia	Biological: T cell injection targeting CD7 chimeric antigen receptor	PersonGen BioTherapeutics (Suzhou) Co., Ltd. The First Affiliated Hospital of Zhengzhou University	Phase 1
NCT04460248	Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naïve Patients With Diffuse Large B-cell Lymphoma (DLBCL)	Diffuse Large B Cell Lymphoma	Drug: Zanubrutinib, Lenalidomide and Rituximab (ZR2)	Ruijin Hospital	Phase 2
NCT04495296	A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors	Advanced Cancer	Biological: TST001 injection	Mabspace Biosciences (Suzhou) Co., Ltd. Beijing Cancer Hospital First Affiliated Hospital of Zhejiang University	Phase 1
NCT04456387	An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.	Hemophilia A	Drug: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection	Zhengzhou Gensciences Inc Haimen Gensciences Inc	Phase 3
NCT04426825	A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	Drug: Atezolizumab Drug: Bevacizumab	Hoffmann-La Roche	Phase 2
NCT04329429	A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer	Biliary Tract Cancer	Drug: RC48-ADC	RemeGen	Phase 2
NCT04340193	A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer	Liver Cancer	Biological: nivolumab Biological: ipilimumab	Bristol-Myers Squibb	Phase 3
NCT04494425	Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer	Advanced or Metastatic Breast Cancer	Drug: Trastuzumab deruxtecan Drug: Capecitabine Drug: Paclitaxel Drug: Nab-Paclitaxel	AstraZeneca Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo	Phase 3

○ 일본 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04340193	A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer	Liver Cancer	Biological: nivolumab Biological: ipilimumab	Bristol-Myers Squibb	Phase 3
NCT04338269	A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment	Carcinoma, Renal Cell	Drug: Atezolizumab Drug: Cabozantinib	Hoffmann-La Roche Exelixis	Phase 3
NCT04434092	A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.	Paroxysmal Nocturnal Hemoglobinuria	Drug: Crovalimab Drug: Eculizumab	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04471428	Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy	Carcinoma, Non-Small-Cell Lung	Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel	Hoffmann-La Roche Exelixis	Phase 3
NCT04240704	Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)	Non-Hodgkins Lymphoma Chronic Lymphocytic Leukemia	Drug: JBH492	Novartis Pharmaceuticals Novartis	Phase 1